McLaughlin Kristin J, Crowther Caroline A
Department of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, Adelaide, South Australia, Australia.
Aust N Z J Obstet Gynaecol. 2003 Jun;43(3):199-202. doi: 10.1046/j.0004-8666.2003.00048.x.
Repeat prenatal corticosteroids have been in common use worldwide, even though the National Institutes of Health recommends that 'Until data establish a favourable benefit-to-risk ratio, repeat courses of antenatal corticosteroids, including rescue therapy, should be reserved for patients enrolled in clinical trials.'
To describe the current use/recommendations for the use of repeat prenatal corticosteroids by obstetricians and neonatologists and to examine the sources of evidence on which their practice is based.
Postal questionnaire.
All Trainees, Members and Fellows of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists and neonatologists in Australia and New Zealand.
The questionnaire was mailed to obstetricians and neonatologists in August-September 2001.
Practitioner use/recommendations for the use of repeat prenatal corticosteroids and the sources of evidence on which their practice was based.
Use of repeat prenatal corticosteroids was recommended by 332 (44%) obstetricians and 19 (21%) neonatologists. Obstetricians were twice as likely to recommend their use compared with neonatologists (relative risk, 2.04; 95% confidence intervals, 1.36-3.06; P < 0.001). Over half of the respondents (483, 57%) reported they had changed their use/recommendations in the previous 3 years. The sources of evidence behind these practices differed between obstetricians and neonatologists and between those practitioners who recommended the use of repeat prenatal corticosteroids and those who did not.
Fewer practitioners recommend repeat prenatal corticosteroids compared with previous surveys. Sources of evidence behind the practice of groups of obstetricians and neonatologists differ.
尽管美国国立卫生研究院建议“在数据证明其风险效益比有利之前,重复使用产前皮质类固醇,包括急救治疗,应仅用于参加临床试验的患者”,但重复使用产前皮质类固醇在全球范围内仍普遍使用。
描述产科医生和新生儿科医生目前对重复使用产前皮质类固醇的使用情况/建议,并检查他们临床实践所依据的证据来源。
邮寄问卷调查。
澳大利亚和新西兰皇家妇产科医师学院以及澳大利亚和新西兰的新生儿科医生的所有实习生、成员和研究员。
问卷于2001年8月至9月邮寄给产科医生和新生儿科医生。
从业者对重复使用产前皮质类固醇的使用情况/建议以及他们临床实践所依据的证据来源。
332名(44%)产科医生和19名(21%)新生儿科医生建议使用重复产前皮质类固醇。与新生儿科医生相比,产科医生推荐使用的可能性是其两倍(相对风险,2.04;95%置信区间,1.36 - 3.06;P < 0.001)。超过一半的受访者(483名,57%)报告称他们在过去3年中改变了使用情况/建议。产科医生和新生儿科医生之间,以及推荐使用重复产前皮质类固醇的从业者和不推荐使用的从业者之间,这些临床实践背后的证据来源有所不同。
与之前的调查相比,推荐重复使用产前皮质类固醇的从业者较少。产科医生和新生儿科医生群体临床实践背后的证据来源不同。